FDA Announces Public Meeting of Oncologic Drugs Advisory Committee to Discuss Minimal Residual Disease Endpoint in Multiple Myeloma Clinical Trials

Summary

The FDA is hosting a public meeting of its Oncologic Drugs Advisory Committee to gather input on the use of minimal residual disease as an endpoint in multiple myeloma clinical trials, with public comments accepted through a newly established docket.